Obesity Update: Radella’s MD-18, Korglutide’s Oral Entry, Liraglutide Launches, Novo’s Forecast Cuts & More
In this week’s Obesity Updates, we spotlight the most pivotal developments reshaping obesity care—from emerging alternatives to GLP-1 therapies and rapid global launches to strategic pharma shifts and intensified market pressure.
🔬 Key Highlights This Week:
💊 Radella’s MD-18 shows weight loss in 28 days—without muscle loss or side effects
🇰🇷 Korglutide, South Korea’s oral GLP-1 rival, claims 10.75% weight loss
🇪🇬 Mounjaro® KwikPen launches in Egypt amid high national BMI rates
🇧🇷 EMS rolls out liraglutide pens, paving the way for generic semaglutide in Brazil
🇨🇳 China’s first domestic obesity drug approved as market heads toward $7.5B by 2030
🇮🇳 Dr. Reddy’s sets timeline for global generic Wegovy launch across 87 countries
🇰🇷 Novo Nordisk teams up with Chong Kun Dang to stay competitive in South Korea
📉 Novo Nordisk cuts 2025 forecasts as market competition intensifies
Whether you’re a clinician, investor, or strategist in obesity therapeutics, this episode delivers fast, expert-curated insights into the future of weight loss innovation.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #GLP1 #RadellaMD18 #Korglutide #Mounjaro #Wegovy #Liraglutide #NovoNordisk #PharmaNews #LucidQuest #HealthcareInnovation #WeightLossDrugs #BiotechUpdates #GlobalHealth #ClinicalTrials